• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-K filed by Nemaura Medical Inc.

    7/1/24 7:00:02 AM ET
    $NMRD
    Medical/Dental Instruments
    Health Care
    Get the next $NMRD alert in real time by email
    NT 10-K 1 nmrd_nt10k.htm FORM 12B-25

     

     

     

      UNITED STATES OMB APPROVAL
      SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058
      Washington, D.C. 20549 Expires: April 30, 2025
        Estimated average burden hours per response ... 2.50
      FORM 12b-25  
        001-38355
      NOTIFICATION OF LATE FILING SEC FILE NUMBER

     

    (Check one):   ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR
         
        For Period Ended: March 31, 2024
         
        ☐ Transition Report on Form 10-K
         
        ☐ Transition Report on Form 20-F
         
        ☐ Transition Report on Form 11-K
         
        ☐ Transition Report on Form 10-Q
         
        ☐ Transition Report on Form N-SAR
         
        For the Transition Period Ended:

     

    Read Instruction (on back page) Before Preparing Form. Please Print or Type.

     

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

    PART I — REGISTRANT INFORMATION

     

    Nemaura Medical Inc.

    Full Name of Registrant

     

    N/A

    Former Name if Applicable

     

    57 West 57th Street

    Address of Principal Executive Office (Street and Number)

     

    Manhattan, NY 10019

    City, State and Zip Code

     

     

     

     

     

    PART II — RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

      (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
       
    ☒ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
       
      (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III — NARRATIVE

     

    State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    The filing by Nemaura Medical Inc. (the “Company”) of the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2024 (the “Annual Report”) will be delayed due to the additional time that was required to obtain and compile certain information required to be included in the Annual Report, which delay could not be eliminated by the Company without unreasonable effort and expense. The Company expects to file the Annual Report within the 15 calendar day extension period. 

     

    PART IV — OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification

     

    Laura Anthony, Esq.   (561)   514-0936
    (Name)   (Area Code)   (Telephone Number)

     

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
       
      Yes ☒ No ☐
       
    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
       
      Yes ☐ No ☒ 
       
      If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

     

     

     

    NEMAURA MEDICAL INC.

    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: June 27, 2024 By: /s/ Dewan F.H. Chowdhury
      Name: Dewan F.H. Chowdhury
      Title: Chief Executive Officer

     

     

     

    Get the next $NMRD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NMRD

    DatePrice TargetRatingAnalyst
    3/29/2022$12.00Buy
    H.C. Wainwright
    12/2/2021$7.50Buy
    EF Hutton
    More analyst ratings

    $NMRD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CRAIG D. LINDER SELECTED TO 2024 TOP 50 LAWYERS IN AMERICA

      WEST PALM BEACH, Fla., April 11, 2024 /PRNewswire/ --   Anthony, Linder & Cacomanolis, PLLC is proud to announce that Partner Craig D. Linder has been selected to the 2024 Top 50 Lawyers in America list for securities law. This prestigious accolade is part of the 10th annual list honoring a select group of 50 lawyers who have demonstrated outstanding leadership and success within the securities law community in the Americas. America's Top 50 Lawyers identifies and highlights the accomplishments of the nation's most distinguished and skilled attorneys in all fields of practice of law. Only 50 lawyers in each state will receive this honor and be selected for this esteemed membership. This hon

      4/11/24 10:00:00 AM ET
      $FUBO
      $HOUR
      $HTCR
      $MOBQ
      Movies/Entertainment
      Consumer Discretionary
      Catalog/Specialty Distribution
      EDP Services
    • Important Update on Listing Status and Strategic Direction

      Loughborough, UK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. ("Nemaura Medical" or the "Company"), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs, is providing a crucial update regarding recent decisions that will impact Nemaura Medical's listing status on The Nasdaq Capital Market and our broader strategic direction. Background: After thorough analysis, Nemaura Medical's Board of Directors and management team have made the strategic decision to accept Nasdaq's determination to delist Nemaura Medical and move to the OTC Markets. This decision arises from a careful consideration of several factors, including challenges outside of our cont

      1/3/24 7:00:00 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care
    • Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision

      Loughborough, UK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ:NMRD) ("Nemaura Medical" or the "Company"), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce that the Nasdaq Hearings Panel granted the Company's request for continued listing pursuant to an exception, including certain interim milestones, that ultimately expires on April 1st, 2024, to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market. The Company plans to continue with its commercial endeavours while pursuing its plans to ensure timely compliance with the terms of the Nasdaq Hearing Panel's decision

      12/13/23 8:00:00 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care

    $NMRD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ghadar-Ghadr Arash bought $14,000 worth of shares (100,000 units at $0.14) (SEC Form 4)

      4 - Nemaura Medical Inc. (0001602078) (Issuer)

      1/9/24 5:30:57 PM ET
      $NMRD
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Ghadar-Ghadr Arash

      3 - Nemaura Medical Inc. (0001602078) (Issuer)

      1/9/24 5:29:16 PM ET
      $NMRD
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Natha Salim

      4 - Nemaura Medical Inc. (0001602078) (Issuer)

      2/1/22 4:13:05 PM ET
      $NMRD
      Medical/Dental Instruments
      Health Care

    $NMRD
    SEC Filings

    See more
    • Nemaura Medical Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Nemaura Medical Inc. (0001602078) (Filer)

      9/26/24 9:21:38 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14C filed by Nemaura Medical Inc.

      DEF 14C - Nemaura Medical Inc. (0001602078) (Filer)

      7/1/24 7:59:03 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care
    • SEC Form NT 10-K filed by Nemaura Medical Inc.

      NT 10-K - Nemaura Medical Inc. (0001602078) (Filer)

      7/1/24 7:00:02 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care

    $NMRD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ghadar-Ghadr Arash bought $14,000 worth of shares (100,000 units at $0.14) (SEC Form 4)

      4 - Nemaura Medical Inc. (0001602078) (Issuer)

      1/9/24 5:30:57 PM ET
      $NMRD
      Medical/Dental Instruments
      Health Care

    $NMRD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Nemaura Medical with a new price target

      H.C. Wainwright initiated coverage of Nemaura Medical with a rating of Buy and set a new price target of $12.00

      3/29/22 7:19:31 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care
    • EF Hutton initiated coverage on Nemaura Medical with a new price target

      EF Hutton initiated coverage of Nemaura Medical with a rating of Buy and set a new price target of $7.50

      12/2/21 8:50:25 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care

    $NMRD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Nemaura Medical Inc.

      SC 13G - Nemaura Medical Inc. (0001602078) (Subject)

      2/14/24 1:54:39 PM ET
      $NMRD
      Medical/Dental Instruments
      Health Care

    $NMRD
    Leadership Updates

    Live Leadership Updates

    See more
    • Nemaura Medical Announces Appointment of Mr Nikolai Rozanov as Strategic Adviser in Artificial Intelligence, to Assist in Development of its AI Health Coach, and Strengthen Outcomes in its CGM Based Metabolic and Type 2 Diabetes Programs.

      LOUGHBOROUGH, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the appointment of Nikolai Rozanov as strategic adviser in AI development. Mr Rozanov is a specialist in the field of artificial intelligence and was selected for inclusion by Forbes magazine in their '30 Under 30' list in the field of technology, a prestigious honour accorded to the best up-and-coming talent in the sector. The appointment of Mr Rozanov solidifies the Company's expertise in

      9/26/23 9:50:00 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care
    • Nemaura Medical Appoints Dr. Arash Ghadar as Chief Operating Officer

      Loughborough, England, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ:NMRD)("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces the appointment of Dr. Arash (Ash) Ghadar as Chief Operating Officer. "Ash will play an important role at Nemaura as we begin to scale up our manufacturing and distribution operations. He brings over 20 years of product development, management and leadership experience spanning both business and technical disciplines. His main area of expertise is in the medical devices sector, and primarily w

      1/10/22 8:00:00 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care
    • Nemaura Medical Appoints Samantha Sanders as Global Head of Digital Programs

      Loughborough, England, April 15, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the appointment of Samantha Sanders as its Global Head of Digital Programs. Samantha has over two decades of project development, management and customer service experience, delivering successful digital projects to market within the wellbeing, pharmaceutical and medical device sector, both locally and internationally.  Prior to joining the Nemaura team, more recently Samantha has bee

      4/15/21 8:07:00 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care

    $NMRD
    Financials

    Live finance-specific insights

    See more
    • Nemaura Medical, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

      ORLANDO, FL / ACCESSWIRE / November 4, 2022 / RedChip Companies will air a new interview with Nemaura Medical, Inc. (NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, on The RedChip Money Report® on Bloomberg TV, this Saturday, November 5, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Interview highlights:In the exclusive RedChip Money Report interview, Nemaura's CEO Dr. Faz Chowdhury discusses Nemaura's continuous glucose sensor, the sugarBEAT®, its potential impact on the 500

      11/4/22 8:00:00 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care
    • Nemaura Medical Reports Financial Results and Provides Business Update for the Fiscal Year Ended March 31, 2022

      Loughborough, England, June 30, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today provides a business update and releases its financial results for the fiscal year ended March 31, 2022. Corporate Highlights for FY2022: Commenced shipments of sugarBEAT® continuous glucose monitor (CGM) devices to its UK licensee, MySugarWatch Limited ("MSWL"), previously DB Ethitronix Limited. MSWL commenced mass educational and awareness campaigns to physicians in the UK via a

      6/30/22 8:00:00 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care
    • Nemaura Medical Reports Financial Results and Provides Business Update for the First Fiscal Quarter Ended June 30, 2021

      Loughborough, England, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ:NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today provides a business update and releases its financial results for the first fiscal quarter, ended June 30, 2021, of fiscal 2022. Recent Corporate Highlights: Launched a digital healthcare subscription service in the U.S. under the brand name BEAT®diabetes, targeted at over 25 million people with Type 2 diabetes and 88 million people with pre-diabetes in the U.S.Received positive feedback fro

      8/16/21 8:30:00 AM ET
      $NMRD
      Medical/Dental Instruments
      Health Care